- Trials with a EudraCT protocol (1,495)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (67)
1,495 result(s) found for: Hepatitis A.
Displaying page 75 of 75.
EudraCT Number: 2008-006439-12 | Sponsor Protocol Number: INSIGHT001:STARTDAIDSID#10619 | Start Date*: 2009-05-25 |
Sponsor Name:Regents of the University of Minnesota | ||
Full Title: Strategic Timing of AntiRetroviral Treatment(START) | ||
Medical condition: HIV Infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) FI (Completed) ES (Completed) DE (Completed) GB (GB - no longer in EU/EEA) GR (Completed) IT (Completed) SE (Completed) PT (Completed) IE (Completed) EE (Completed) NO (Completed) AT (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005127-34 | Sponsor Protocol Number: 0518-018 | Start Date*: 2006-03-14 | |||||||||||
Sponsor Name:Merck & Co. Inc. | |||||||||||||
Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 in Combination With an Optimized Background Therapy (OBT), Versus Opt... | |||||||||||||
Medical condition: Unspecified human immuno-deficiency virus [HIV] disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) ES (Completed) PT (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003884-71 | Sponsor Protocol Number: LPS13649 | Start Date*: 2015-02-05 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab Extension Study (CAMMS03409) | |||||||||||||
Medical condition: Relapsing-remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) CZ (Completed) ES (Completed) DE (Completed) IT (Completed) DK (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000783-25 | Sponsor Protocol Number: 0518-032 | Start Date*: 2007-05-23 | |||||||||||
Sponsor Name:Merck Sharp & Dohme de España, S.A. | |||||||||||||
Full Title: A Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus KALETRA™ in HIV-Infected Patients Switched from a Stable KALE... | |||||||||||||
Medical condition: HIV Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000864-94 | Sponsor Protocol Number: EORTC protocol 10054 | Start Date*: 2007-01-15 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC) | |||||||||||||
Full Title: A phase I-II study of lapatinib and docetaxel as neoadjuvant treatment for HER-2 positive locally advanced/inflammatory or large operable breast cancer. | |||||||||||||
Medical condition: Locally advanced/inflammatory or large operable brest cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) GB (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003960-20 | Sponsor Protocol Number: NN7008-3543 | Start Date*: 2009-06-26 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Prevention and Treatment of Bleeds in Previously Treated Subjects with Haemophilia A Sub-Trial: Safety and Efficacy ... | |||||||||||||
Medical condition: Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005362-36 | Sponsor Protocol Number: SiLVER 05 | Start Date*: 2006-06-27 | |||||||||||
Sponsor Name:Regensburg University Hospital | |||||||||||||
Full Title: A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA | |||||||||||||
Medical condition: Prophylaxis against liver transplant rejection in patients undergoing liver transplantation for hepatocellular carcinoma (HCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) GB (Completed) SE (Completed) BE (Completed) NO (Completed) AT (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001592-30 | Sponsor Protocol Number: V72P12 | Start Date*: 2008-06-11 | |||||||||||
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | |||||||||||||
Full Title: A Phase 2b, Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered with... | |||||||||||||
Medical condition: The Novartis Meningococcal B Recombinant + OMV NZ Vaccine is intended for prevention of meningitidis and/or septicemia caused by N.meningitidis serogroup B. The objective of the Novartis Meningococ... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) ES (Completed) IT (Completed) BE (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006226-34 | Sponsor Protocol Number: EFC10891 | Start Date*: 2009-03-25 |
Sponsor Name:sanofi-aventis recherche et development | ||
Full Title: Estudio multicéntrico, aleatorizado, de grupos paralelos, ciego para el evaluador, que compara la efectividad y seguridad de teriflunomida e interferón beta-1a en pacientes con esclerosis múltiple ... | ||
Medical condition: Esclerosis Múltiple ------------------------ Multiple sclerosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) DE (Completed) HU (Completed) CZ (Completed) IT (Completed) GR (Completed) FR (Completed) BE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-004941-34 | Sponsor Protocol Number: GFT505B-319-1 | Start Date*: 2020-10-09 | |||||||||||
Sponsor Name:IPSEN Pharma SAS | |||||||||||||
Full Title: A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Ina... | |||||||||||||
Medical condition: Primary Biliary Cholangitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-018077-31 | Sponsor Protocol Number: 012010 | Start Date*: 2010-11-25 |
Sponsor Name:St. Anna Kinderkrebsforschung/CCRI | ||
Full Title: A PHASE I/II DOSE SCHEDULE FINDING STUDY FOR CH14.18/CHO CONTINUOUS INFUSION COMBINED WITH SUBCUTANEOUS ALDESLEUKIN (IL-2) IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSING NEUROBLASTOMA | ||
Medical condition: High-risk neuroblastoma patients having received at least one previous high dose treatment followed by stem cell rescue after conventional therapy fulfilling one of the following criteria: • Prima... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) ES (Ongoing) DE (Completed) IT (Ongoing) GB (GB - no longer in EU/EEA) IE (Completed) PL (Completed) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003171-39 | Sponsor Protocol Number: T-Control | Start Date*: 2016-03-08 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:University Hospital Wuerzburg | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Transfer of Streptamer-selected multi-antigen specific T cells to prevent infections and relapse and to reduce the risk of Graft-versus-Host Disease after allogeneic stem cell transplantation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: patients with hematological malignancies after T cell depleted allo-SCT | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023178-37 | Sponsor Protocol Number: GS-US-264-0106 | Start Date*: 2011-02-04 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/... | |||||||||||||
Medical condition: Human Immunodeficiency Virus (Type 1) Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) ES (Completed) BE (Completed) IT (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016138-29 | Sponsor Protocol Number: APL-C-001-09 | Start Date*: 2010-05-06 | |||||||||||
Sponsor Name:Pharma Mar, S.A. | |||||||||||||
Full Title: “Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Patients with Relapsed/Refractory Multiple Myeloma”. | |||||||||||||
Medical condition: Relapsed/Refractory Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Completed) ES (Completed) AT (Completed) NL (Completed) DE (Completed) BE (Completed) CZ (Completed) IT (Completed) GR (Completed) IE (Completed) PT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001087-30 | Sponsor Protocol Number: CT-P13_3.8 | Start Date*: 2019-07-25 | |||||||||||
Sponsor Name:Celltrion, Inc | |||||||||||||
Full Title: A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients With Moderat... | |||||||||||||
Medical condition: Moderately to Severely Active Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) CZ (Completed) SK (Completed) FR (Completed) PL (Completed) DE (Completed) GR (Completed) HU (Completed) ES (Completed) AT (Completed) BG (Completed) HR (Completed) IT (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
